| TNDM Stock Rises Despite Q1 Earnings Miss, Gross Margin Up |
Tandem Diabetes' Q1 bottom line lags estimate. However, the company experiences strong sales growth both in and outside the United States. |
zacks.com |
2025-05-02 13:06:07 |
Czytaj oryginał (ang.) |
| Tandem Diabetes Care, Inc. (TNDM) Q1 2025 Earnings Conference Call Transcript |
Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Susan Morrison - EVP & Chief Administrative Officer John Sheridan - President & CEO Leigh Vosseller - EVP & CFO Conference Call Participants Matt Miksic - Barclays Mat Blackman - Stifel Steve Lichtman - Oppenheimer & Company Matthew O'Brien - Piper Sandler David Roman - Goldman Sachs Matthew Taylor - Jeffries Chris Pasquale - Nephron Research Anthony Petrone - Mizuho Financial Groups Joshua Jennings - TD Cowen Issie Kirby - Redburn Atlantic Nathan Trebek - Wells Fargo Mike Kratky - Leerink Partners Jayson Bedford - Raymond James & Associates William Plovanic - Canaccord Genuity Michael Polark - Wolfe Research Danielle Antalffy - UBS Stephanie Piazzolla - Bank of America Securities Shagun Singh - RBC Operator Good day, and thank you for standing by. Welcome to the Tandem Diabetes Care First Quarter 2025 Earnings Conference Call. |
seekingalpha.com |
2025-05-01 00:11:49 |
Czytaj oryginał (ang.) |
| Tandem Diabetes Care (TNDM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates |
Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-05-01 00:05:42 |
Czytaj oryginał (ang.) |
| Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates |
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.63 per share a year ago. |
zacks.com |
2025-04-30 22:55:57 |
Czytaj oryginał (ang.) |
| What to Expect From These 3 MedTech Stocks This Earnings Season? |
Here is a sneak peek into how these three MedTech stocks, ALGN, TNDM and ICLR, may fare in their quarterly results, slated to be released tomorrow. |
zacks.com |
2025-04-29 14:15:47 |
Czytaj oryginał (ang.) |
| Reasons to Hold TNDM Stock in Your Portfolio for Now |
A robust diabetes market and international expansion raise investors' optimism for Tandem Diabetes. |
zacks.com |
2025-04-17 14:01:05 |
Czytaj oryginał (ang.) |
| Tap Into the Silver Economy Boom With These Aging Demographics Stocks |
The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health. |
zacks.com |
2025-04-14 20:00:39 |
Czytaj oryginał (ang.) |
| 2 Beaten-Down Stocks to Avoid in the Tariff-Fueled Correction |
With equity markets reeling due to President Donald Trump's tariffs, many investors are taking this opportunity to buy shares of top companies on the dip. It's a great strategy, but it's essential to avoid those companies that only look undervalued but actually aren't. |
fool.com |
2025-04-12 18:05:00 |
Czytaj oryginał (ang.) |
| Tandem Diabetes Care (TNDM) Moves 7.6% Higher: Will This Strength Last? |
Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2025-04-10 13:51:27 |
Czytaj oryginał (ang.) |
| Tandem Diabetes Care to Announce First Quarter 2025 Financial Results on April 30, 2025 |
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2025 results after the financial markets close on Wednesday, April 30, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2025 financial and operating results. A live webcast of the call will be available on Tandem Diabe. |
businesswire.com |
2025-04-03 20:05:00 |
Czytaj oryginał (ang.) |
| TNDM Stock Gains on the Commercial Launch of Control-IQ+ Technology |
Tandem Diabetes launches Control-IQ+ technology commercially in the United States. Control-IQ+ is compatible with t:slim X2 insulin pump and Tandem Mobi System. |
zacks.com |
2025-03-19 12:21:03 |
Czytaj oryginał (ang.) |
| Tandem Diabetes Care Launches New Control-IQ+ Automated Insulin Delivery Technology in the United States |
SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced the United States commercial launch of Control-IQ+ technology, the latest generation of the company's advanced hybrid closed-loop algorithm. Control-IQ+, compatible with both the t:slim X2 insulin pump and Tandem Mobi System, is now available for people with type 1 diabetes ages 2 years and older and adults with type 2 diabetes. Pumps pre-loaded with. |
businesswire.com |
2025-03-18 18:05:00 |
Czytaj oryginał (ang.) |
| Reasons to Hold TNDM Stock in Your Portfolio for Now |
A robust product innovation and several strategic developments raise investors' optimism for Tandem Diabetes. |
zacks.com |
2025-03-11 11:46:13 |
Czytaj oryginał (ang.) |
| Tandem Diabetes Q4 Earnings Review: I Don't Share The Market's Skepticism |
Tandem Diabetes Care, Inc. released its Q4 and full-year 2024 earnings after the bell yesterday, and the market has given the stock the thumbs down. Shares are down >30% in trading today, despite a beat on revenues of $940m, and on EPS, with a return to positive cash flow. Guidance for 2025 is for revenues of ~$1bn — the growth rate does not seem to have impressed Wall Street, and Q4 underperformance issues also played a part. |
seekingalpha.com |
2025-02-27 14:44:29 |
Czytaj oryginał (ang.) |
| TNDM Stock Falls in Aftermarket Following Q4 Earnings and Revenue Miss |
Tandem Diabetes' Q4 top and bottom lines lag their respective estimate. However, the company experiences strong sales growth both in and outside the United States. |
zacks.com |
2025-02-27 11:45:31 |
Czytaj oryginał (ang.) |
| Tandem Diabetes Care, Inc. (TNDM) Q4 2024 Earnings Call Transcript |
Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Susan Morrison - Executive Vice President & Chief Administrative Officer John Sheridan - President & Chief Executive Officer Mark Novara - Executive Vice President & Chief Commercial Officer Leigh Vosseller - Executive Vice President & Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Steve Lichtman - Oppenheimer & Company Matt Miksic - Barclays Chris Pasquale - Nephron Research Larry Biegelsen - Wells Fargo Shagun Singh - RBC Mike Kratky - Leerink Partners Danielle Antalffy - UBS Jayson Bedford - Raymond James William Plovanic - Canaccord Genuity Mike Polark - Wolfe Research Matthew O'Brien - Piper Sandler Joshua Jennings - TD Cowen Jeff Johnson - Baird Travis Steed - Bank of America Operator Good day and welcome to the Tandem Diabetes Fourth Quarter and Year-End 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-02-27 03:04:03 |
Czytaj oryginał (ang.) |
| Here's What Key Metrics Tell Us About Tandem Diabetes Care (TNDM) Q4 Earnings |
While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-02-26 22:00:22 |
Czytaj oryginał (ang.) |
| Tandem Diabetes Care, Inc. (TNDM) Reports Q4 Loss, Lags Revenue Estimates |
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.27 per share a year ago. |
zacks.com |
2025-02-26 20:30:27 |
Czytaj oryginał (ang.) |
| Tandem Diabetes Care Announces Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance |
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter and fiscal year ended December 31, 2024 and provided its financial guidance for the year ending December 31, 2025. Fourth Quarter 2024 Financial Highlights compared to Fourth Quarter 2023 Achieved record sales as worldwide GAAP sales grew 44 percent to $282.6 million and worldwide non-GAAP sales(1) grew 21 percent. |
businesswire.com |
2025-02-26 18:05:00 |
Czytaj oryginał (ang.) |
| Tandem Diabetes Care (TNDM) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures |
Evaluate the expected performance of Tandem Diabetes Care (TNDM) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. |
zacks.com |
2025-02-25 12:20:55 |
Czytaj oryginał (ang.) |
| Tandem Diabetes Care Announces FDA Clearance of Control-IQ+ Automated Insulin Delivery Technology for People with Type 2 Diabetes |
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--Control-IQ+ automated insulin delivery technology from Tandem Diabetes Care cleared by FDA for people with type 2 diabetes. |
businesswire.com |
2025-02-25 10:30:00 |
Czytaj oryginał (ang.) |
| Tandem Diabetes Gains 45.7% in a Year: What's Driving the Stock? |
TNDM's shares rise as its expanding product portfolio gains market traction. However, the unfavorable macroeconomic scenario is concerning. |
zacks.com |
2025-01-22 10:26:12 |
Czytaj oryginał (ang.) |
| Reasons to Retain TNDM Stock in Your Portfolio for Now |
A robust diabetes market and several strategic developments raise investors' optimism for Tandem Diabetes. |
zacks.com |
2025-01-21 09:11:16 |
Czytaj oryginał (ang.) |
| Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 |
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2024 results after the financial markets close on Wednesday, February 26, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its fourth quarter and full year 2024 financial and operating results. A live webcast of the call. |
businesswire.com |
2025-01-15 18:05:00 |
Czytaj oryginał (ang.) |
| Tandem Diabetes Forges New R&D Agreement With UVA: Stock to Gain? |
TNDM enters a multi-year research collaboration with the UVA Center for Diabetes Technology for the development of AID systems. |
zacks.com |
2025-01-09 11:20:41 |
Czytaj oryginał (ang.) |
| Tandem Diabetes Care Enters Multi-Year Research Collaboration with UVA Center for Diabetes Technology for Development of Advanced Insulin Delivery Systems |
SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced it has signed a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology (UVA) to advance research and development efforts on fully automated closed-loop insulin delivery systems. The research collaboration will rely on the UVA Center for Diabetes Technology's groundbreaking work to improve care for patients w. |
businesswire.com |
2025-01-07 11:00:00 |
Czytaj oryginał (ang.) |
| TNDM Stock to Gain From t:slim X2 With Dexcom G7 Launch in Canada |
Tandem Diabetes' t:slim X2 insulin pump is now compatible with Dexcom G7 CGM in Canada. |
zacks.com |
2024-12-13 11:45:28 |
Czytaj oryginał (ang.) |
| Reasons to Retain TNDM Stock in Your Portfolio for Now |
Innovations and a robust international market expansion raise investors' optimism for Tandem Diabetes. |
zacks.com |
2024-12-06 11:51:31 |
Czytaj oryginał (ang.) |
| Tandem Diabetes Care Announces Upcoming Conference Presentations |
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences: 36th Annual Piper Sandler Healthcare Conference on Tuesday, December 3, 2024 at 8:00am Eastern Time (5:00am Pacific Time), and Citi's 2024 Global Healthcare Conference on Wednesday, December 4, 2024 at 1:00pm Eastern Time (10:00am Pacific Time). The presentations wil. |
businesswire.com |
2024-11-21 18:05:00 |
Czytaj oryginał (ang.) |
| TNDM Q3 Earnings Beat, '24 Sales View Up, Stock Falls in Aftermarket |
Tandem Diabetes' top and bottom lines outpace estimates in the third quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi. |
zacks.com |
2024-11-08 11:31:14 |
Czytaj oryginał (ang.) |
| Tandem Diabetes Care, Inc. (TNDM) Q3 2024 Earnings Conference Call Transcript |
Tandem Diabetes Care, Inc. (TNDM) Q3 2024 Earnings Conference Call Transcript |
seekingalpha.com |
2024-11-06 23:21:04 |
Czytaj oryginał (ang.) |
| Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say |
While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2024-11-06 21:36:30 |
Czytaj oryginał (ang.) |
| Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Tops Revenue Estimates |
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.38 per share a year ago. |
zacks.com |
2024-11-06 20:26:08 |
Czytaj oryginał (ang.) |
| Tandem Diabetes Care Announces Upcoming Conference Participation |
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will host meetings and present a company update at the following investor conferences: UBS Global Healthcare Conference on Thursday, November 14, 2024 at 11:45am Eastern Time (8:45am Pacific Time), Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024 at 11:30am Eastern Time (8:30am Pacific Time), Jefferies London Healthcare. |
businesswire.com |
2024-10-30 18:05:00 |
Czytaj oryginał (ang.) |
| Down -21.69% in 4 Weeks, Here's Why Tandem Diabetes Care (TNDM) Looks Ripe for a Turnaround |
Tandem Diabetes Care (TNDM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
zacks.com |
2024-10-18 14:35:24 |
Czytaj oryginał (ang.) |
| Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says |
RBC Capital Markets initiated coverage on Tandem Diabetes Care, Inc. TNDM, a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. |
benzinga.com |
2024-10-02 18:11:55 |
Czytaj oryginał (ang.) |
| Why Tandem Diabetes Care Stock Took It on the Chin Tuesday |
Flat revenue growth might be in store for the company in a very crucial market. |
fool.com |
2024-10-01 21:39:23 |
Czytaj oryginał (ang.) |
| t:slim X2's Compatibility With Lilly's Lyumjev Might Aid TNDM Stock |
By integrating ultra-rapid acting insulin such as Lyumjev, which responds faster than traditional insulin, Tandem Diabetes Care is enhancing the pump's functionality. |
zacks.com |
2024-10-01 17:37:11 |
Czytaj oryginał (ang.) |
| TNDM Stock Likely to Gain From Innovation Amid Competition |
Tandem Diabetes is driving transformative innovation to help reduce the burden of diabetes and create new possibilities for people living with the condition. |
zacks.com |
2024-09-23 14:32:17 |
Czytaj oryginał (ang.) |
| TNDM Stock Likely to Benefit From the t:slim X2-Lyumjev Offering in EU |
Tandem Diabetes' t:slim X2 insulin pump is now compatible with Lilly's Lyumjev in the European Union. |
zacks.com |
2024-09-23 13:35:15 |
Czytaj oryginał (ang.) |
| Why Tandem Diabetes Care Stock Thrashed the Market Today |
It earned a regulatory nod in one of the largest markets in the world. Approval was granted for a system to deliver an ultra-rapid insulin product developed by Eli Lilly. |
fool.com |
2024-09-19 22:49:08 |
Czytaj oryginał (ang.) |
| Tandem t:slim X2 Insulin Pump Now Compatible with Lyumjev Ultra-rapid Acting Insulin in European Union |
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2 insulin pump with Control-IQ automated insulin delivery (AID) technology is now cleared for use with Eli Lilly and Company's Lyumjev® (insulin lispro-aabc injection) ultra-rapid acting insulin in the European Union (EU). “High satisfaction and quality of life benefits were recently shown in a clinical study using Lyumjev with Contr. |
businesswire.com |
2024-09-19 13:00:00 |
Czytaj oryginał (ang.) |
| Reasons to Hold Tandem Diabetes Stock in Your Portfolio Now |
Innovations and a robust diabetes market outlook raise investors' optimism for TNDM. |
zacks.com |
2024-09-03 13:40:54 |
Czytaj oryginał (ang.) |
| New Launches Support Tandem Diabetes Stock Despite Macro Concerns |
The latest addition to TNDM's pump platform portfolio, Tandem Mobi, is leading the way in creating a whole new category of devices for insulin therapy. |
zacks.com |
2024-08-30 16:25:57 |
Czytaj oryginał (ang.) |
| Tandem Diabetes Care to Release Updated iOS t:connect Mobile App for t:slim X2 Insulin Pump Users Impacted by March 2024 Nationwide Recall |
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) today announced the planned release of version 2.8.2 of its Apple iOS t:connect mobile app in the United States on August 20, 2024 to correct an issue described in a March 2024 recall that can cause rapid depletion of a user's t:slim X2 insulin pump battery. This battery depletion can result in the pump shutting down sooner than expected, which some customers have continued to see following the release of version 2.7.1 of the. |
businesswire.com |
2024-08-19 22:30:00 |
Czytaj oryginał (ang.) |
| Tandem Diabetes Care Provides Update on March 2024 Nationwide Recall of t:connect Mobile App for iOS Devices |
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) today provided an update on the March 2024 recall of its Apple iOS t:connect mobile app in the United States relating to an issue that can cause rapid depletion of a user's t:slim X2 insulin pump battery. This battery depletion can result in the pump shutting down sooner than expected, which some customers have continued to experience following the release of version 2.7.1 of the app in March. Notices were emailed to impacted. |
businesswire.com |
2024-08-12 20:30:00 |
Czytaj oryginał (ang.) |